Transcription‐mediated amplification blood donation screening for Babesia. Issue 2 (29th December 2019)

• Record Type: Journal Article
• Authors: Tonnetti, Laura; Young, Carolyn; Kessler, Debra A.; Williamson, Phillip C.; Reik, Rita; Proctor, Melanie C.; Brès, Vanessa; Deisting, Barbara; Bakkour, Sonia; Schneider, William; Diner, Samara; Busch, Michael P.; Stramer, Susan L.; Linnen, Jeffrey M.
• Is Part Of: Transfusion. Volume 60:Issue 2(2020)
• Page Start: 317
• Page End: 325
• Publication Date: 2019-12-29
• Subjects: Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; Blood Group Antigens -- Periodicals; Blood Preservation -- Periodicals; Blood Transfusion -- Periodicals; 615
• DOI: 10.1111/trf.15630
• Languages: English
• ISSNs: 0041-1132

Abstract

Abstract : BACKGROUND: Transfusion‐transmitted Babesia microti is well recognized in the Northeast and upper Midwestern United States. Blood donation screening in Babesia ‐endemic states has occurred under investigational protocols prior to US Food and Drug Administration–licensed test availability. Here, we provide a prospective screening summary of nucleic acid testing (NAT) as part of a multicenter Babesia pivotal trial followed by extended investigational use. METHODS: From June 2017 to February 2018, 176, 928 donation samples were tested with Procleix Babesia Assay (Grifols Diagnostic Solutions), a blood screening NAT for Babesia species ribosomal RNA detection using whole blood samples. During the pivotal trial, donations were collected in 11 endemic states plus Washington, DC, and Florida (nonendemic). Whole blood lysate samples were either tested in pools of 16 or individually. Reactive samples were confirmed by Babesia microti antibody and polymerase chain reaction (PCR) testing. If unconfirmed, further testing used a second PCR assay capable of detecting multiple Babesia species. Follow‐up samples were also tested. Extended investigational testing followed pivotal trial completion. RESULTS: The pivotal trial identified 61 confirmed positives (176, 608 donations): 35 (57%) PCR positive, 59 (97%) antibody positive, and two (3%) NAT positive/antibody negative, for a total yield of one positive per 2895 donations, including one Florida resident; others were from seven endemic states. During extended investigational testing of 496, 270 donations in endemic states through January 2019, 211 (1:2351) repeat reactive donations were identified. CONCLUSIONS: Babesia was detected in donors from multiple US states, including one previously not associated with positive blood donors. This study supports the use of the Procleix Babesia Assay using individual testing or pools of up to 16.